133 related articles for article (PubMed ID: 14706249)
1. Development of a perillyl alcohol topical cream formulation.
Gupta A; Myrdal PB
Int J Pharm; 2004 Jan; 269(2):373-83. PubMed ID: 14706249
[TBL] [Abstract][Full Text] [Related]
2. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.
Stratton SP; Alberts DS; Einspahr JG; Sagerman PM; Warneke JA; Curiel-Lewandrowski C; Myrdal PB; Karlage KL; Nickoloff BJ; Brooks C; Saboda K; Yozwiak ML; Krutzsch MF; Hu C; Lluria-Prevatt M; Dong Z; Bowden GT; Bartels PH
Cancer Prev Res (Phila); 2010 Feb; 3(2):160-9. PubMed ID: 20103724
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats.
de Lima DC; Rodrigues SV; Boaventura GT; Cho HY; Chen TC; Schönthal AH; Da Fonseca CO
Drug Test Anal; 2020 Feb; 12(2):268-279. PubMed ID: 31800149
[TBL] [Abstract][Full Text] [Related]
4. Preformulation, formulation, and in vivo efficacy of topically applied apomine.
Kuehl PJ; Stratton SP; Powell MB; Myrdal PB
Int J Pharm; 2009 Dec; 382(1-2):104-10. PubMed ID: 19699284
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer.
Stratton SP; Saboda KL; Myrdal PB; Gupta A; McKenzie NE; Brooks C; Salasche SJ; Warneke JA; Ranger-Moore J; Bozzo PD; Blanchard J; Einspahr JG; Dorr RT; Levine N; Alberts DS
Nutr Cancer; 2008; 60(3):325-30. PubMed ID: 18444166
[TBL] [Abstract][Full Text] [Related]
6. An HPLC method for quantitation of perillyl alcohol in a topical pharmaceutical cream formulation.
Gupta A; Stratton SP; Myrdal PB
J Pharm Biomed Anal; 2005 Mar; 37(3):447-52. PubMed ID: 15740902
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
8. The Release of Perillyl Alcohol from the Different Kind of Vehicles.
Miastkowska M; Konieczna M; Lason E; Tabaszewska M; Sikora E; Ogonowski J
Curr Pharm Biotechnol; 2018; 19(7):573-580. PubMed ID: 30062959
[TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatographic and pharmacokinetic analyses of an intravenous submicron emulsion of perillyl alcohol in rats.
Hua HY; Zhao YX; Liu L; Ye QX; Ge SW
J Pharm Biomed Anal; 2008 Dec; 48(4):1201-5. PubMed ID: 18849133
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
11. Development of an HPLC method for the analysis of Apomine in a topical cream formulation.
Kuehl PJ; Angersbach BS; Stratton SP; Myrdal PB
J Pharm Biomed Anal; 2006 Mar; 40(4):975-80. PubMed ID: 16181759
[TBL] [Abstract][Full Text] [Related]
12. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention.
Proniuk S; Liederer BM; Blanchard J
J Pharm Sci; 2002 Jan; 91(1):111-6. PubMed ID: 11782902
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
14. Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1α via mTOR/4E-BP1 signaling pathways.
Ma J; Li J; Wang KS; Mi C; Piao LX; Xu GH; Li X; Lee JJ; Jin X
Int Immunopharmacol; 2016 Oct; 39():1-9. PubMed ID: 27394002
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of perillyl alcohol administered daily.
Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation.
Barthelman M; Chen W; Gensler HL; Huang C; Dong Z; Bowden GT
Cancer Res; 1998 Feb; 58(4):711-6. PubMed ID: 9485025
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of perillyl alcohol against cancer cells is potentiated by hyperthermia.
Ahn KJ; Lee CK; Choi EK; Griffin R; Song CW; Park HJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):813-9. PubMed ID: 14529788
[TBL] [Abstract][Full Text] [Related]
18. Development and Evaluation of Stability of a Gel Formulation Containing the Monoterpene Borneol.
Dantas MG; Reis SA; Damasceno CM; Rolim LA; Rolim-Neto PJ; Carvalho FO; Quintans-Junior LJ; Almeida JR
ScientificWorldJournal; 2016; 2016():7394685. PubMed ID: 27247965
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol.
Shi W; Gould MN
Carcinogenesis; 2002 Jan; 23(1):131-42. PubMed ID: 11756234
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
